What's in Kures, Inc.'s pipeline?

Kures, Inc. has 2 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Kures, Inc.'s portfolio?

Top competitors by shared drug class: Ain Shams University, Ajay Wasan, MD, Msc, Alza Corporation, DE, USA, Archimedes Development Ltd, Asbjørn Mohr Drewes.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/kures-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Kures, Inc. — Portfolio Competitive Intelligence Brief

Kures, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
OxyNorm	OxyNorm	marketed	Opioid analgesic	Mu (μ) opioid receptor	Pain Management

Therapeutic area mix

Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ain Shams University · 1 shared drug class
Ajay Wasan, MD, Msc · 1 shared drug class
Alza Corporation, DE, USA · 1 shared drug class
Archimedes Development Ltd · 1 shared drug class
Asbjørn Mohr Drewes · 1 shared drug class
BioDelivery Sciences International · 1 shared drug class
Boston Children's Hospital · 1 shared drug class
AdventHealth · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kures, Inc.:

Cite this brief

Drug Landscape (2026). Kures, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kures-inc. Accessed 2026-05-14.